Navigation Links
Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
Date:2/24/2009

17,001 9,601 21,295 27,675 Amortization expense 12,357 13,438 49,973 55,985 215,658 23,039 257,568 83,660 (Gain) loss on early extinguishment of debt (3,327) - 11,555 - Tax on adjustments (18,726) (44) (1,351) (22,985) Total adjustments, net of tax 193,605 22,995 267,772 60,675 Adjusted income from continuing operations $43,155 $25,081 $71,722 $81,285 GAAP earnings per share - diluted $(1.82) $0.02 $(2.24) $0.22 Cash earnings per share - diluted $0.52 $0.28 $0.81 $0.86 Shares used in diluted per share calculation - GAAP earnings per share 82,585 90,978 87,480 93,976 Shares used in adjusted diluted per share calculation - Cash earnings per share 83,738 90,978 88,467 93,976 To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items, such as acquired in-process research and development, restructuring, asset impairments and dispositions, amortization expense and the tax effect of such charges. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a more meaningful, consistent comparison of the company's core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be consider
'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... June 03, 2015 Peter Piot, MD, ... at DIA’s upcoming Annual Meeting. DIA’s Global Inspire Award ... level of excellence, and commitment to service on a ... President’s Award for Outstanding Contribution to Global Health that ... to advancing global health. , “DIA is ...
(Date:6/3/2015)... Visual BI Solutions, a leader in ... launch of the second release of its successful ... Studio. The Design Studio EXtension suite allows customers ... into their dashboarding projects. , With the second ... adding key components for customers that are looking ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Researchers at ... biomarkers for mesothelioma and say the tried-and-true marker mesothelin ... posted an article on the research. Click here ... University’s National Center for Asbestos Related Diseases say, even ... results, it is still preferable to fibulin-3 for identifying ...
(Date:6/3/2015)... 2015 Sitting at a computer for ... the back, neck, shoulders and/or wrists. This can lead ... addition, recent research links sitting for long periods as ... Fortunately, three inventors from Oakville, Ontario, are offering an ... , They have developed a prototype for a patent-pending ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 On Sunday, ... the world will gather in their local communities to ... of cities across the U.S. and abroad will hold ... bring attention to the ongoing challenges of cancer survivorship, ... cancer diagnosis can be fruitful, rewarding, and inspiring.,  , ...
Breaking Medicine News(10 mins):Health News:Co-discoverer of Ebola Virus and AIDS Pioneer to be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Co-discoverer of Ebola Virus and AIDS Pioneer to be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 4
... adipose tissue, or the layer of fat around the heart, ... as coronary artery calcium scoring, according to research by cardiologists ... layer of fat around the heart can be measured by ... information may be used as a ,gate keeper, in that ...
... (March 15, 2010) New research findings published in the ... of Surgeons indicate that some breast cancers continue to ... through mammographic screening. Patients who presented with palpable tumors ... examination had larger tumors and were at a more ...
... Plastic Surgery Arts ... a new reconstructive breast surgery program at Hunterdon Regional Cancer Center. Dr. Nini is a ... , ... -- Plastic Surgery Arts of New Jersey (PSANJ) is proud to announce that Dr. Kevin ...
... March 15 The Dallas-Fort Worth Business Group on Health (DFWBGH), a non-profit coalition of large private and public employers throughout North Texas focused on enhancing the ... ... ... ...
... odds of not drinking, researchers say , MONDAY, March ... Zoloft (sertraline) and the alcoholism drug naltrexone improves the ... dependence will be able to stop drinking, U.S. researchers ... that 54 percent of those who received the combined ...
... ... wrestles with their own Trillion Dollar Question: How do we increase employee productivity ... Inc. the maker of Sweat365.com, unveils “The Healthy Corp” a breakthrough product that ... ...
Cached Medicine News:Health News:Imaging fat layer around heart can help predict disease 2Health News:Palpable breast cancers are more common in women not undergoing annual mammography 2Health News:Palpable breast cancers are more common in women not undergoing annual mammography 3Health News:Dr. Kevin Nini to Lead Reconstructive Breast Surgery Program at Hunterdon Regional Cancer Center 2Health News:Dr. Kevin Nini to Lead Reconstructive Breast Surgery Program at Hunterdon Regional Cancer Center 3Health News:Dallas-Fort Worth Business Group on Health Elects New Board Members 2Health News:Dallas-Fort Worth Business Group on Health Elects New Board Members 3Health News:Konamoxt, Inc. Redefines Corporate Wellness with The Healthy Corp, a Customizable Corporate Wellness Platform 2Health News:Konamoxt, Inc. Redefines Corporate Wellness with The Healthy Corp, a Customizable Corporate Wellness Platform 3
(Date:6/3/2015)... 02, 2015 Research and Markets ( ... "2015 Strategies in the US Tumor Marker ... Highlights of the Report Include ... marker testing market. , Major issues pertaining ... key economic, regulatory, demographic, social and technological trends ...
(Date:6/3/2015)... 2015 Creekridge Capital, an independent, national commercial ... by adding two new sales representatives. Sam Puma ... Manager and Stefanie Stark joined the company ... to Creekridge with over 20 years of vendor and ... Mr. Puma will be responsible for identifying, implementing and ...
(Date:6/3/2015)... , June 3, 2015  Flow cytometry remains ... the globe and keeping track of wide-ranging consumer ... market. In particular, ensuring user-friendliness, fluorescence capabilities, specialized ... the most important factors influencing end-user purchase decisions ... New analysis from Frost & Sullivan, ...
Breaking Medicine Technology:United States Strategies in the Tumor Marker Testing Market 2015 2Creekridge Capital Strengthens Sales Team 2Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 2Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 3Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 4
... Feb.16, 2012 Bionovo, Inc. (OTC Link Platform: BNVI.PK) ... of safe and effective treatments for women,s health and ... call on Tuesday, February 21, 2012 at 1:30 PM ... year ended December 31, 2011. (Logo:  ...
... Feb. 16, 2012  PDL BioPharma, Inc. (PDL) (NASDAQ: ... release its fourth quarter and full year financial results ... February 23, 2012 after market close. PDL,s management will ... 4:30 p.m. Eastern Time to discuss the financial results. ...
Cached Medicine Technology:PDL BioPharma to Announce Fourth Quarter and Full Year 2011 Financial Results on February 23, 2012 2
Plastic Economical Single use. Non-Sterile....
... Portex® Blue Line® uncuffed ... Magill or Murphy styles, in ... ,Blue Line® adult and pediatric ... from implant-tested polyvinyl chloride with ...
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
... Ruschelit® PVC. 2 eyes, oral. Marked ... age. X-ray opaque line. Graduated. Single ... Designed to reduce kinking of the ... Thermosensitive Ruschelit® PVC adapts to the ...
Medicine Products: